PDE9 inhibitors with imidazo triazinone backbone
US-9434733-B2 · Sep 6, 2016 · US
PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US11608342B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11608342-B2 |
| Application number | US-202017115108-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 8, 2020 |
| Priority date | Jul 7, 2015 |
| Publication date | Mar 21, 2023 |
| Grant date | Mar 21, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition comprising compound (3S,4S) -6-(4-methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl)-3-(tetrahydro-pyran-4-yl)-7H -imidazo[1,5-a]pyrazin-8-one and one or more pharmaceutically acceptable carriers, diluents, or excipients, wherein the compounds is present in the composition from 0.01 mg to 1000 mg per dose. 2. The pharmaceutical composition of claim 1 , wherein the compound is present in the composition from 0.05 mg to 500 mg per dose. 3. The pharmaceutical composition of claim 1 , wherein the compound is present in the composition from 0.05 to 200 mg per dose. 4. A method of treating sickle cell disease in a patient in need thereof, comprising administering to the patient from 0.001 mg/kg to 100 mg/kg body weight per day of a compound (3S,4S)-6-(4-methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl)-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one. 5. The method of claim 4 , wherein the compound is administered to the patient from 0.01 mg/kg to 50 mg/kg body weight per day. 6. The method of claim 4 , wherein the compound is administered to the patient from 0.05 mg/kg to 10 mg/kg body weight per day. 7. The method of claim 4 , wherein the compound is administered to the patient orally. 8. The method of claim 4 , wherein the compound is administered to the patient in one to three doses per day.
Assignees
Inventors
Classifications
for impotence · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
of the prostate · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
of urine or of the urinary tract, e.g. urine acidifiers · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11608342B2 cover?
- The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.
- Who is the assignee on this patent?
- H Lundbeck As
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).